Literature DB >> 17294097

Characteristics of the formation of chronic fatigue syndrome and approaches to its treatment in young patients with focal brain damage.

A N Boiko1, T T Batysheva, O V Matvievskaya, T M Manevich, E I Gusev.   

Abstract

Chronic fatigue is among the manifestations of focal brain lesions. It is most often encountered in multiple sclerosis (MS) and patients with the sequelae of traumatic, inflammatory, and vascular brain damage (encephalopathies). The aim of the present work was to study the mechanisms of formation of this syndrome in 50 patients with focal brain lesions of different origins (in the inactive stage) and to assess the possibility of correcting it using the combined agent Fezam (2 capsules t.i.d. for one month), which contains piracetam and cinarrizine. In patients with encephalopathies, chronic fatigue syndrome was directly associated with the severity of depression. Patients with MS showed changes in the value-sense sphere. Neuropsychological testing showed that the psychological and personality components played a greater role in the origins of chronic fatigue in patients with encephalopathies than in those with MS. Fezam significantly decreased the severity of chronic fatigue, particularly in patients with MS; in the second group (non-MS patients) this was accompanied by a decrease in the severity of depression. Mild side effects (in six patients--12%) consisted generally of sleep disturbances. These results indicate that Fezam should be used in the treatment of chronic fatigue in patients with focal brain lesions; in encephalopathies it should be combined with psychoactive agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17294097     DOI: 10.1007/s11055-007-0005-8

Source DB:  PubMed          Journal:  Neurosci Behav Physiol        ISSN: 0097-0549


  9 in total

1.  A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis.

Authors:  B G Weinshenker; M Penman; B Bass; G C Ebers; G P Rice
Journal:  Neurology       Date:  1992-08       Impact factor: 9.910

2.  Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study.

Authors:  U Roelcke; L Kappos; J Lechner-Scott; H Brunnschweiler; S Huber; W Ammann; A Plohmann; S Dellas; R P Maguire; J Missimer; E W Radü; A Steck; K L Leenders
Journal:  Neurology       Date:  1997-06       Impact factor: 9.910

3.  On the effect of calcium antagonists on cerebral blood flow in rats. A comparison of nimodipine and flunarizine.

Authors:  M Zumkeller; H E Heissler; H Dietz
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

4.  Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.

Authors:  L B Krupp; P K Coyle; C Doscher; A Miller; A H Cross; L Jandorf; J Halper; B Johnson; L Morgante; R Grimson
Journal:  Neurology       Date:  1995-11       Impact factor: 9.910

5.  An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis.

Authors:  G L Sheean; N M Murray; J C Rothwell; D H Miller; A J Thompson
Journal:  Brain       Date:  1998-05       Impact factor: 13.501

6.  Characterization of 4-aminopyridine in overdose.

Authors:  C M Stork; R S Hoffman
Journal:  J Toxicol Clin Toxicol       Date:  1994

Review 7.  Memory function and brain glucose metabolism.

Authors:  S Hoyer
Journal:  Pharmacopsychiatry       Date:  2003-06       Impact factor: 5.788

8.  Fatigue in MS is associated with specific clinical features.

Authors:  C Colosimo; E Millefiorini; M G Grasso; F Vinci; M Fiorelli; T Koudriavtseva; C Pozzilli
Journal:  Acta Neurol Scand       Date:  1995-11       Impact factor: 3.209

9.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

  9 in total
  1 in total

Review 1.  Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.

Authors:  Andrei G Malykh; M Reza Sadaie
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.